Antibody Class and Target Shape Disease Phenotype and Treatment in Cicatricial Pemphigoid and Related Conditions
View StudyPlain-Language Summary
A new review clarifies how the type of antibody driving cicatricial pemphigoid and related subepidermal blistering diseases influences both what the condition looks like and how it should be treated. Whether the culprit autoantibodies belong to the IgE, IgG, IgM, or IgA class can substantially affect clinical presentation and therapeutic decisions. This distinction is especially important for patients with ocular cicatricial pemphigoid, where prompt and appropriately targeted treatment is critical for preserving vision.
Abstract
Subepidermal blistering diseases are driven by autoantibodies targeted to the basement membrane zone. These autoantibodies can stem from multiple antibody classes, including IgE, IgG, IgM, and IgA, and differing antibody classes and targets can substantially impact disease phenotype and potentially management strategies.
Despite significant advances in the field, a paucity of data and research funding has limited further elucidation of subepidermal blistering disease pathophysiology and its implications for management. This review synthesizes current knowledge on antibody targets and classes, and the impact these distinctions have on clinical phenotype and disease course.
Conditions highlighted include bullous pemphigoid, mucous membrane pemphigoid (including ocular cicatricial pemphigoid), linear IgA disease, and epidermolysis bullosa acquisita. For each condition, the authors examine how antibody profile shapes disease manifestations and informs treatment choices, underscoring the value of thorough immunopathological workup at the time of diagnosis.